The global chemotherapy induced anemia market is anticipated to register growth over the forecast period.
Anemia is a condition wherein there is a decrease in the total amount of red blood cells or haemoglobin in the blood. Haemoglobin is an essential part of the red blood cells and binds oxygen. In case of low or abnormal red blood cells the cells in the body will not receive appropriate amount of oxygen.
There are different types of anemia such as anemia caused by blood loss, anemia caused due to destruction of red blood cells, anemia caused due to decreased or faulty red blood cell production, etc. The major factor that propels the growth of the global Chemotherapy Induced Anemia market include rise in the occurrence of cancer and anemia among geriatric patients.
In addition, there are also other key factors such as bone marrow invasion, rise in chronic inflammatory conditions, upsurge in pipeline products, innovations in the technology, and reimbursement policy.
Also, there are side effects of the cancer treatment which can develop anemia and increase in several causes of anemia in cancer patients are also projected to drive the growth of the global Chemotherapy Induced Anemia market. On the other hand, there are also factors that hinder the growth of the market such as side effects of drugs and risk related with treatment.
The global chemotherapy Induced Anemia market is classified on the basis of range of anemia, treatment type, drug type, end user and geography. On the basis of range of anemia, the global market is classified as mild anemia, moderate anemia, severe anemia and life-threatening anemia.
On the basis of treatment type, the global Chemotherapy Induced Anemia market is classified as Erythropoiesis-stimulating agents (ESAs), Iron Supplementation and RBC Transfusions.
On the basis of drug type, the global market is classified as Androxy Oral, Epoetin Alfa Injection, Epogen Injection, Procrit Injection, Aranesp injection and others
On the basis of end-user, the global market is classified as hospitals, ambulatory surgical centers, multispecialty clinics, cancer research centers and cancer rehabilitation centers. On the basis of geography, the global Chemotherapy Induced Anemia market is classified as North America, Latin America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
The North American region comprises the U.S., and Canada. Latin America comprises Mexico, Brazil, and Argentina. The Western European region comprises Germany, Italy, England, Spain, France, Nordic, and Rest of Western Europe. The Eastern European region comprises Russia, and Poland. Asia Pacific region comprises China, India, ASEAN, and Australia & New Zealand. The Middle East and Africa comprises GCC, South Africa, and North Africa.
In case of geographical region, Asia Pacific dominates a major share of the global Chemotherapy Induced Anemia market. The Asia Pacific market is followed by Europe, Japan and North America due to great awareness about the disease among people, innovations in the field of chemotherapy induced anemia, government initiatives, and technologically advanced healthcare infrastructure in these regions.
In addition, Asia Pacific, Middle East and Africa hold great prospective and demonstrate a considerable growth rate in case of extensive acceptance of new technology due to occurrence of anemia among cancer patients, high death rate, growing disposable on healthcare expenditure and an increased necessity of treatment for chemotherapy induced anemia.
Some of the prominent players that fuel the growth of the global Chemotherapy Induced Anemia Market include Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Panacea Biotec., Panacea Biotec Limited, 3SBio Inc., SBI Pharmaceuticals Co., Ltd, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, and Therapure Biopharma Inc.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.